Skip to main content
Equibles

TUDOR INVESTMENT CORP ET AL

Position in SLS — SELLAS Life Sciences Group, Inc.

CIK 923093 STAMFORD, CT
Back to SLS Full portfolio

Position in SLS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
3 quarters on record

Derivatives in SLS

reported options exposure · as of Jun 30, 2026
CallValue
$2,069,352
CallShares
140,200
PutValue
$3,087,792
PutShares
209,200

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

TUDOR INVESTMENT CORP ET AL holds $414,135,114 across 107 Biotechnology names.

# Ticker Company Shares Value (USD) Open
1 TECH
BIO-TECHNE Corp
 943,287 $66,643,226
2 RPRX
Royalty Pharma plc
 610,736 $34,243,967
3 XENE
Xenon Pharmaceuticals Inc.
 545,387 $32,919,559
4 ABVX
Abivax S.A.
 187,335 $24,964,262
5 INSM
INSMED Inc
 195,391 $20,832,588
6 MLYS
Mineralys Therapeutics, Inc.
 738,370 $19,921,222
7 ABCL
AbCellera Biologics Inc.
 2,063,191 $16,196,049
8 QURE
uniQure N.V.
 328,889 $15,148,627

All Filings in SLS

Export CSV
6 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $3,087,792 209,200
2026-06-30 $2,069,352 140,200
2026-03-31 $671,724 158,800
2026-03-31 $658,188 155,600
2025-12-31 $2,585,089 685,700
2025-12-31 $2,328,352 617,600